Kamada Ltd (KMDA) stock

KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026Score 5/30

$8.09−0.04 (-0.49%)

Close on Nov 13, 2026Market cap $466.68MP/E –Yield –

Earnings

Kamada's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 9, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

$54.90M

+22.5% on a year earlier

EPS, Q2 FY2026

$0.16

$0.13 a year earlier

Latest guidance

Reaffirmed

Aug 12, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Kamada's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 9, 2026Expected	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 12, 2026before the open	$54.90M	+22.5%	$0.16	Release
Q1 FY2026ended Mar 31, 2026	May 13, 2026before the open	$45.20M	+2.7%	$0.07	Release
Q4 FY2025ended Dec 31, 2025	Mar 11, 2026before the open	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 10, 2025before the open	$47.00M	+12.7%	$0.09	Release
Q2 FY2025ended Jun 30, 2025	Aug 13, 2025before the open	$44.80M	–	$0.13	Release
Q1 FY2025ended Mar 31, 2025	May 14, 2025before the open	$44.00M	–	$0.07	Release
Q4 FY2024ended Dec 31, 2024	Mar 5, 2025before the open	–	–	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 13, 2024before the open	$41.70M	–	$0.07	Release
Q4 FY2023ended Dec 31, 2023	Mar 6, 2024before the open	$36.40M	–	$0.09	Release
Q2 FY2023ended Jun 30, 2023	Aug 16, 2023before the open	$37.40M	–	$0.04	Release
Q1 FY2023ended Mar 31, 2023	May 24, 2023before the open	–	–	–	Release
Q4 FY2022ended Dec 31, 2022	Mar 15, 2023before the open	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 22, 2022before the open	–	–	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 17, 2022before the open	–	–	–	Release
Q1 FY2022ended Mar 31, 2022	May 17, 2022before the open	–	–	–	Release
Q4 FY2021ended Dec 31, 2021	Mar 15, 2022before the open	–	–	–	Release
Q3 FY2021ended Sep 30, 2021	Nov 22, 2021before the open	–	–	–	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Kamada's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
total revenuesGAAP	FY2026	$200.00M – $205.00M	$200.00M – $205.00M	Reaffirmed	Aug 12, 2026
adjusted EBITDAnon-GAAP	FY2026	$50.00M – $53.00M	$50.00M – $53.00M	Reaffirmed	Aug 12, 2026

Guidance history

Every forecast Kamada put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 12, 2026	adjusted EBITDA	FY2026	$50.00M – $53.00M	Reaffirmed
Aug 12, 2026	total revenues	FY2026	$200.00M – $205.00M	Reaffirmed
May 13, 2026	adjusted EBITDA	FY2026	$50.00M – $53.00M	New
May 13, 2026	total revenues	FY2026	$200.00M – $205.00M	New
Nov 10, 2025	adjusted EBITDA	FY2025	$40.00M – $44.00M	Reaffirmed
Nov 10, 2025	total revenues	FY2025	$178.00M – $182.00M	Reaffirmed
Aug 13, 2025	adjusted EBITDA	FY2025	$40.00M – $44.00M	Raised
Aug 13, 2025	revenue	FY2025	$178.00M – $182.00M	New
May 14, 2025	adjusted EBITDA	FY2025	$38.00M – $42.00M	New
May 14, 2025	total revenues	FY2025	$178.00M – $182.00M	New
Nov 13, 2024	adjusted EBITDA	FY2024	$32.00M – $35.00M	Raised
Nov 13, 2024	total revenues	FY2024	$158.00M – $162.00M	New
Mar 6, 2024	adjusted EBITDA	FY2024	$27.00M – $30.00M	New
Mar 6, 2024	total revenues	FY2024	$156.00M – $160.00M	New
Aug 16, 2023	adjusted EBITDA	FY2023	$22.00M – $26.00M	New
Aug 16, 2023	total revenues	FY2023	$138.00M – $146.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.